Dermatitis Atopic Clinical Trial
Official title:
A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants (≥6 to <15 Years of Age) With Moderate-to-severe Atopic Dermatitis
This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping (STS) in approximately 48 pediatric participants (aged ≥6 and <15 years at study entry) with moderate-to-severe AD. All eligible participants with AD will be treated with Dupixent® for 104 weeks according to locally approved Dupixent® product label (in country/region where the study is conducted). After the 104-week treatment phase and the last assessment at the End of Treatment (EoT), participants will be followed-up for 4 weeks and an End-of-Study (EoS) visit by telephone at 4 weeks after the EoT visit will end the study for each participant. The maximum duration of the study per participant will be 112 weeks (including screening period). The study population will include approximately 48 pediatric participants with AD for long-term treatment with dupilumab: - Treatment cohort 1 - newly recruited participants with AD (aged ≥6 to <12 years at study entry) - Treatment cohort 2 - any former PELISTAD participants (from the previous 16-week treatment study [PELISTAD/LPS16764] who consent to participate in this long-term study; aged ≥6 to <15 years at entry to this study)
Study duration for each participant will be approximately 112 weeks, including: - Screening period: Up to 4 weeks (Day -28 to Day -1) from signing the informed consent. - Open-label dupilumab treatment period: 104 weeks (from Day 1/Week 0 to Week 104). - Follow-up period: 4 weeks (safety follow-up phone visit at 4 weeks after the EoT visit). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06015308 -
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
|
Phase 2 | |
| Completed |
NCT04135560 -
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT06130566 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT06192563 -
A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
|
||
| Completed |
NCT05624112 -
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
|
Phase 4 | |
| Active, not recruiting |
NCT03992417 -
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
|
||
| Recruiting |
NCT06224348 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
|
Phase 3 | |
| Completed |
NCT05214326 -
A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries
|
||
| Recruiting |
NCT06241118 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
|
Phase 3 | |
| Completed |
NCT04718870 -
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT05235724 -
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
|
||
| Recruiting |
NCT06181435 -
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
|
Phase 3 | |
| Recruiting |
NCT05492578 -
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
|
Phase 2 | |
| Recruiting |
NCT03687359 -
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
|
||
| Active, not recruiting |
NCT03849716 -
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
|
||
| Recruiting |
NCT05769777 -
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04823130 -
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
|
Phase 4 |